pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
mimivax PRESS RELEASE ARCHIVE
Dec 15, 2022
MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology
Nov 15, 2021
MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
May 30, 2020
MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients
Nov 18, 2019
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China
May 29, 2019
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
May 21, 2018
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
May 15, 2018
MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
